Mechanisms of action for green tea extract in breast cancer prevention identified

October 18 2012

An oral green tea extract, Polyphenon E, appears to inhibit vascular endothelial growth factor and hepatocyte growth factor, both of which promote tumor cell growth, migration and invasion.

Researchers made this discovery during a secondary analysis of a phase Ib randomized, placebo-controlled study of Polyphenon E in a group of 40 women with hormone receptor-negative breast cancer. Katherine D. Crew, M.D., assistant professor of medicine and epidemiology at Columbia University Medical Center in New York, N.Y., presented the data at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 16-19, 2012.

"Many preclinical studies have looked at epigallocatechin-3-gallate, or EGCG, which is one of the main components of green tea, and the various possible mechanisms of its action against cancer, but it is very difficult to do those same kinds of studies in humans," Crew said. "This study was too small to say for sure if green tea will prevent breast cancer, but it may move us forward in terms of understanding antitumor mechanisms."

In the primary analysis, presented at last year's Frontiers in Cancer Prevention Research meeting, 40 women were randomly assigned to 400 mg, 600 mg or 800 mg of Polyphenon E or to placebo twice daily for six months. During that time, researchers collected blood and urine samples from participants at baseline and at two, four and six months.
In this secondary analysis, Crew and colleagues used the blood and urine samples to examine biologic endpoints, such as inflammatory proteins, growth factors and lipid biomarkers, which might point to the mechanism of action behind green tea extract. Biomarker data were available for 34 of the 40 patients.

Women assigned to the extract had an average 10-fold increase in green tea metabolites compared with placebo. In addition, they had a significant reduction in hepatocyte growth factor levels at two months compared with women assigned to placebo. However, at the four-month and six-month follow-ups, the difference was no longer statistically significant.

The researchers also identified a trend toward decreased total serum cholesterol and decreased vascular endothelial growth factor in women assigned to the extract.

According to Crew, it is still too early to recommend green tea extract to prevent breast cancer. Currently, researchers are conducting several ongoing studies to explore the use of oral green tea extract in high-risk women for the primary prevention of breast cancer.

**More information:** A73 Evaluating tissue biomarker effects of an oral green tea extract, Polyphenon E, using reverse phase protein array in women with operable breast cancer. Kimberly A. Ho et al.

**Abstract**
Background: Numerous epidemiologic studies and experimental data support potential anti-tumor effects of green tea and its main component, epigallocatechin-3-gallate (EGCG), in breast cancer. However, there is limited data on the effects of tea catechins on breast cancer in human intervention trials. The purpose of this study is to evaluate tumor proteomic changes after short-term pre-surgical
administration of an oral green tea extract, Polyphenon E (Poly E), in
women with operable breast cancer using reverse phase protein array
(RPPA).

Methods: This is a phase II single-arm open-label trial of oral Poly E 800
mg daily for 2-4 weeks in women with histologically-confirmed breast
cancer on core biopsy who were scheduled for surgical resection.
Formalin-fixed paraffin-embedded (FFPE) tumor tissue from the
diagnostic core biopsy (pre-treatment) and surgical resection (post-
treatment) were analyzed for expression of the Ki-67 proliferation index,
estrogen receptor (ER), progesterone receptor (PR), and HER2 by
immunohistochemistry (IHC). Protein was extracted for RPPA analysis
of 161 proteins, including components of the PI3K/AKT and MAPK
pathways. Women were matched by age, breast cancer stage,
ER/PR/HER2 status, and time interval between breast biopsy and
surgery to untreated historical controls. Paired t-test was used to
calculate changes in protein markers before and after Poly E treatment
and 2-sample t-test to compare biomarker changes in the treatment and
no treatment groups. All statistical analyses were 2-sided and performed
using SAS version 9.1.

Results: From Feb 2008 to Sept 2009, 25 women were enrolled and 21
were evaluable. Median age: 50 years (range, 33-71);
White/Hispanic/Black (%): 44/48/7; Stage 0/I/II/III (%): 11/48/30/11;
hormone receptor +/- (%): 85/15. Mean duration on Poly E was 20 days
(range, 13-36). We demonstrated significant correlations between RPPA
and IHC for Ki-67 (0.46, P

Citation: Mechanisms of action for green tea extract in breast cancer prevention identified (2012,
October 18) retrieved 7 October 2023 from